Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750513 · ClinicalTrials.gov registry record · Phase 1
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
A Phase 1 study of Ependymoma and Anaplastic Ependymoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT03750513 is a Phase 1 study of Ependymoma and Anaplastic Ependymoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 102-participant average among 20 other Ependymoma trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03750513, a Phase 1 study of Ependymoma and Anaplastic Ependymoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- RADIATION Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03750513
The ClinicalTrials.gov registry entry for NCT03750513 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 20 other Ependymoma trials with a reported enrollment target (53% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ependymoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03750513 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT03750513 about?
NCT03750513 is a clinical study titled "LET Optimized IMPT in Treating Pediatric Patients With Ependymoma". This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surroundi...
What is the current status of trial NCT03750513?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-04-01. Estimated completion is 2027-12-31.
What conditions does trial NCT03750513 study?
This clinical trial studies the following conditions: Ependymoma, Anaplastic Ependymoma.
What interventions are being tested in trial NCT03750513?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy (RADIATION).
Who is sponsoring clinical trial NCT03750513?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03750513 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ependymoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
RECRUITING · Phase 1
-
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
RECRUITING · Phase 1
-
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
RECRUITING · Phase 1
-
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.